Gheorghiade M, Hall V B, Jacobsen G, Alam M, Rosman H, Goldstein S
Division of Biostatistics, Henry Ford Heart and Vascular Institute, Detroit, Mich, USA.
Circulation. 1995 Oct 1;92(7):1801-7. doi: 10.1161/01.cir.92.7.1801.
Despite almost three centuries of use, the appropriate dosage of digitalis in patients with chronic heart failure and normal sinus rhythm has not been well studied.
We studied 22 patients with heart failure who were receiving constant daily doses of digoxin, diuretics, and angiotensin-converting enzyme (ACE) inhibitors. In 18 patients, the oral daily dose of digoxin was increased from a mean of 0.20 +/- 0.07 to 0.39 +/- 0.11 mg/day corresponding to an increase in the serum digoxin concentration from 0.67 +/- 0.22 to 1.22 +/- 0.35 ng/mL. Radionuclide and echocardiographic left ventricular ejection fraction; maximal treadmill time; heart failure score; serum concentrations of norepinephrine, aldosterone, atrial natriuretic factor, and antidiuretic hormone; and plasma renin activity were obtained before and after the increase in digoxin dose. Subsequently, 9 patients were randomized to receive digoxin and 9 to receive placebo and radionuclide ejection fraction measured after 12 weeks. With the higher dose of digoxin compared with the lower dose, there was a significant increase in radionuclide ejection fraction from 23.7 +/- 9.6% to 27.1 +/- 11.8% (P = .007). No significant changes were noted in heart failure score; exercise tolerance; serum concentrations of norepinephrine, atrial natriuretic factor, and antidiuretic hormone; and plasma renin activity. There was, however, an increase in serum aldosterone concentration. Twelve weeks after the patients were randomized to receive digoxin or placebo, there was a significant decrease in ejection fraction (from 29.4 +/- 10.4% to 23.7 +/- 8.9%) in the placebo group but not in patients who continued to receive digoxin (P = .002).
The increase in maintenance digoxin dose, while maintaining serum concentrations within therapeutic range, resulted in a significant increase in left ventricular ejection fraction that was not associated with significant changes in heart failure score, exercise tolerance, and neurohumoral profile.
尽管洋地黄已使用了近三个世纪,但慢性心力衰竭且窦性心律正常患者的洋地黄合适剂量尚未得到充分研究。
我们研究了22例接受固定每日剂量地高辛、利尿剂和血管紧张素转换酶(ACE)抑制剂治疗的心力衰竭患者。18例患者地高辛口服日剂量从平均0.20±0.07毫克/天增加至0.39±0.11毫克/天,相应地高辛血清浓度从0.67±0.22纳克/毫升增至1.22±0.35纳克/毫升。在增加地高辛剂量前后,获取了放射性核素和超声心动图左心室射血分数、最大平板运动时间、心力衰竭评分、去甲肾上腺素、醛固酮、心房利钠因子和抗利尿激素的血清浓度以及血浆肾素活性。随后,9例患者随机接受地高辛治疗,9例接受安慰剂治疗,并在12周后测量放射性核素射血分数。与低剂量相比,高剂量地高辛使放射性核素射血分数从23.7±9.6%显著增至27.1±11.8%(P = 0.007)。心力衰竭评分、运动耐量、去甲肾上腺素、心房利钠因子和抗利尿激素的血清浓度以及血浆肾素活性均无显著变化。然而,血清醛固酮浓度有所升高。患者随机接受地高辛或安慰剂治疗12周后,安慰剂组射血分数显著降低(从29.4±10.4%降至23.7±8.9%),而继续接受地高辛治疗的患者则未出现这种情况(P = 0.002)。
维持地高辛剂量增加,同时将血清浓度维持在治疗范围内,可使左心室射血分数显著增加,且与心力衰竭评分、运动耐量和神经体液状态的显著变化无关。